bluuebunny/crossref_metadata_2025_split huggingface dataset:
Adriamycin, BCNU, and cyclophosphamide in drug‐resistant adenocarcinoma of the ovary
Authors: Presant Cary A. , Bartolucci Alfred 
Published: February 2007

AbstractBecause of an encouraging response rate in a pilot study of adriamycin, BCNU, and cyclophosphamide (ABC), the Southeastern Cancer Study Group conducted a phase II study of ABC in patients with melphalan‐resistant ovarian carcinoma. Of 36 evaluable patients, there were only 4 partial responses to therapy, for a partial response rate of 11%. Durations of response were 4 to 50 + weeks, and the overall median survival was 29 weeks. No complete responses were seen. Dose‐limiting toxicity was granulocytopenia. We conclude that ABC is generally ineffective in management of alkylator‐resistant ovarian adenocarcinoma.
Asymptomatic intracardiac metastasis from osteosarcoma: A case report with literature review
Authors: Das Lakshmi , Farooki Zia Q. , Hakimi Mehdi N. , Philippart Arvin I. , Watts Frederick B. , Arciniegas Eduardo , Cushing Barbara , Ryan James 
Published: February 2007

AbstractOsteosarcoma very rarely metastasizes to the heart. Thirteen cases have been reported in the literature so far. Diagnosis in some of these cases was made during investigation for severe cardiac failure and in most of them at autopsy. Our patient, a 13‐year‐old girl, showed right pulmonary metastases on chest x‐ray 1 year after above knee amputation for osteosarcoma of the distal femur. Routine preoperative computerized axial tomography (CT Scan) revealed a calcified lesion in the heart in addition to the pulmonary metastases. She was very active and completely asymptomatic. Two‐dimensional echocardiography, angiography, and right and left heart catheterizations were done. This revealed a large mobile metastatic lesion in the right ventricle. The intraventricular tumor was successfully removed, and 12 days later she had a second thoracotomy for removal of pulmonary metastases. Nine months after her intraventricular metastasis was removed she developed a solitary right pulmonary metastasis. This was successfully resected. Now, 10 months later, she is disease free and completely asymptomatic.
Brief communication: Legionnaire's disease successfully treated in acute myelocytic leukemia during severe neutropenia
Authors: Guthrie Troy H. , Mahizhnan Palarmalai 
Published: February 2007

AbstractA patient with acute nonlymphocytic leukemia developed progressive lung infiltrates and unremitting fevers during a profound neutropenic state. Legionnaire's disease was diagnosed by simple immunologic studies and successfully treated with erythromycin.This index case alerts physicians toward a treatable infection which would not normally be susceptible to the empiric antibiotic regimens given neutropenic patients with fevers.
Clinical aspects of the rhabdoid tumor of the kidney: A report of the national wilms' tumor study group
Authors: Palmer Nigel F. , Sutow Wataru 
Published: February 2007

AbstractRhabdoid tumor of the kidney (RTK), originally described as a monophasic sarcomatous variant of Wilms' tumor, is now recognized as a highly malignant, non‐Wilms' tumor possibly of neuroectodermal origin. Twenty‐one National Wilms' Tumor Study patients with this tumor were treated in the years 1969 through 1978. Mean patient age was 18 months with 16 of the 21 younger than 2 years at diagnosis. Two patients were Stage I, 10 Stage II, 5 Stage III, and 4 Stage IV. One patient only is continuously disease free and another is surviving disease free following excision of bilateral pulmonary metastases. One patient died of sepsis early during therapy. Thus 18 of the 19 patients who relapsed died, 15 within 1 year of diagnosis, all with progressive tumor growth. The rapid appearance of metastases (mean 4 months), often to multiple sites, and short subsequent survival signal a very malignant tumor resistant to current treatment stratagems.
Central nervous system toxicity of high‐dose cytosine arabinoside
Authors: Grossman L. , Baker M. A. , Sutton D. M. C. , Deck J. H. N. 
Published: February 2007

AbstractTen patients with refractory acute leukemia were treated with high‐dose cytosine arabinoside (Ara‐C) infusions. Nine patients had previously achieved at least one complete remission using standard chemotherapy protocols that include cytosine arabinoside. Eight of the ten had been on maintenance therapy. Twelve courses of treatment were given, with the cytosine arabinoside infused over 1‐2 hours in a dose of 3 gm/m2. Each course consisted of 12 to 16 doses given at 12‐hour intervals.The drug was generally well tolerated but five patients developed central nervous system symptoms characterized by ataxia, dysphasia, nystagmus, dysdiadochokinesis, and a decreased level of consciousness. These changes began 3 to 34 days after the initiation of therapy and were severe at the time of death in two of the patients. One complete and one partial remission, lasting 2.5 months and 1 month, respectively, were documented. This experience suggests that high‐dose AraC is of limited usefulness in refractory acute leukemia and may be frequently associated with significant neurotoxicity.
Primary chemotherapy followed by radiotherapy for localized non‐hodgkin's lymphomas: A preliminary report
Authors: Sampi Kazumi , Takeoda Syozi , Hattori Masao 
Published: February 2007

AbstractTwenty‐eight evaluable patients with clinical stage I‐II of non‐Hodgkin's lymphoma were treated with primary chemotherapy followed by involved field radiotherapy. The frequency of the follicular versus diffuse histological pattern was 14.3 versus 85.7%, and 24/28 (86%) of patients were in stage II. No lymphoma examined was identified as T‐cell in origin. A complete response was obtained in 21 (78%) of 27 patients with measurable disorder. [Gastrectomy rendered one patient disease‐free survival, and one partially responded showing a complete reponse after radiotherapy.] Sixteen (76%) of the 21 employed for complete response. After 36 months, elapsed disease‐free survival was rated at 100% together with actuarial survival of all patients at 81%. Chemotherapy contributed to reduce the radiation dosage to 3000 rads and to control the areas infiltrated with preexisting tumors. These findings, although the median follow‐up time in our study remains short (28 months), provide a strong rationale for further clinical trials of primary chemotherapy, followed by regional radiotherapy for localized stages of non‐Hodgkin's lymphomas.
Phase II evaluation of galactitol in head and neck cancer: A southwest oncology group study
Authors: Haas Charles D. , Lehane Daniel , Bottomley Richard 
Published: February 2007

AbstractA phase II evaluation of DAG in head and neck cancer patients produced one partial response and one patient with prolonged stable disease from nine fully evaluable patients with squamous carcinomas. One partial response was produced in a patient with anaplastic thyroid carcinoma. No drug deaths or life‐threatening toxicity were reported. Further evaluation of DAG in thyroid tumors is warranted.
Brief communication: Hexamethylmelamine in adenocarcinoma of the pancreas and liver
Authors: Oldham Dwight S. , Wampler Galen L. 
Published: February 2007

AbstractTen patients with advanced adenocarcinoma of the pancreas were treated with hexamethylmelamine 8 mg/kg/day in oral, divided doses. One of the five patients with measurable disease had a partial response which lasted 5 months. One of the five patients with no measurable disease treated for 52 months with hexamethylmelamine survived a total of 59 months. This experience suggests that hexamethylmelamine may be an active drug in the treatment of pancreatic cancer.
Antibody Response to Pneumococcal Vaccine in Patients With Solid Tumors and Lymphomas
Authors: Shildt Richard A. , Boyd James F. , McCracken Joseph D. , Schiffman Gerald , Giolma John Paul 
Published: February 2007

AbstractNinety patients with solid tumors or lymphomas were immunized with a polyvalent pneumococcal vaccine. Pre‐ and postimmunization antibody titers were determined by radioimmunoassay. Treated patients with lymphoma had poor antibody response whether on or off chemotherapy. Patient with chronic lymphocytic leukemia had the lowest antibody titers of all patients groups. Patients with solid tumors had antibody responses which were similar to those of the control population. Those patients who received sequential chemotherapy and immunization had a tendency for higher postimmunization titers than those patients who received simultaneous chemotherapy and immunization, but the difference was not significant. This study suggests that patients with solid tumors would be expected to benefit from pneumococcal immunization, whereas patients with lymphoma immunized after receiving treatment initially would not be expected to develop protective antibody levels. Recovery of antibody formation in patients with non‐Hodgkin lymphoma, which may occur in patients with Hodgkin disease, remains to be determined.
Prognosis in Acute Lymphoblastic Leukemia of Childhood as Determined by Cytogenetic Studies at Diagnosis
Authors: Morse Helvise G. , Odom Lorrie F. , Tubergen David , Hays Taru , Blake Marilyn , Robinson Arthur 
Published: February 2007

AbstractFifty‐one children with acute lymphoblastic leukemia on a common protocol of treatment were classified according to presence or absence of chromosomal abnormalities found at the time of diagnosis in bone marrow and/ or blood. Twenty‐two or 43% had normal karyotypes while 29 (57%) had clonal abnormalities using the Giemsa‐trypsin banding technique. Thirteen of the 29 (45%) chromo‐somally abnormal patients relapsed while only three of 21 (14%) with normal karyotypes have relapsed with a median follow‐up of 49.5 months (42‐76 months). (One child with a normal karyotype did not respond to therapy.) Several hypotheses have been offered to attempt to explain the significantly better prognosis of patients with no observable initial chromosomal aberrations.
Treatment of childhood acute lymphoblastic leukaemia in Malaysia, 1976‐1982
Authors: Lin Hai‐Peng , Sinnah D. , Menaka N. , Cherian R. , Singh P. 
Published: February 2007

AbstractOne hundred four children with acute lymphoblastic leukaemia were diagnosed at the University Hospital, Kuala Lumpur, Malaysia, between 1976 and 1982; 87 were evaluable with respect to treatment. They were divided into good prognosis (GP) and bad prognosis (BP) groups based on their initial total white cell count, their treatment differing only during the maintenance phase. Remission was achieved in 82 patients (94%) of whom ten (12%) subsequently died in remission from infection. Twenty‐eight (34%) relapsed while on treatment and three while off therapy. Eleven patients ceased treatment after 3 yr of continuous complete remission (CCR). Three of these later relapsed, two within the first year. Survival in CCR was significantly better in the GP group up to 30 months, after which the difference diminished. There was no difference in survival between boys and girls. The overall disease‐free survival at 3 yr and 5 yr was 40% and 25%, respectively, with a median follow‐up period of 20 months (range 4‐69 months). The reasons for the relatively low survival rates as compared with those in developed countries are discussed.
Can hypertransfusion attenuate myelosuppression associated with combination chemotherapy in patients with inoperable bronchogenic carcinoma? A report of a randomised, controlled study
Authors: Lam W. K. , So S. Y. , Ng R. P. , Yu D. Y. C. 
Published: February 2007

AbstractBased on the concept of “>Based on the concept of” hypertransfusion has been shown to attenuate the leucopenia associated with chemotherapy in children with leukemia. We conducted a randomized, controlled study of hypertransfusion in 25 patients with inoperable lung cancer who received combination chemotherapy consisting of methotrexate, adriamycin, cyclophosphamide, and CCNU (Lomustine) (MACC scheme). Twelve patients in the hypertransfusion group were given red cell transfusion to a hemoglobin value greater than or equal to 17 gm/dl prior to each chemotherapy cycle. The two groups of patients were comparable in age, cell type, extent of disease, performance status, and initial hemoglobin level and blood counts. The mean fall in granulocyte count was greater for control group (3.76 × 109/liter) than for hypertransfusion group (3.27 × 109/liter), and the mean fall in platelet count was greater for control group (53.84 × 109/liter) than for hypertransfusion group (35.83 × 109/liter), although the differences did not reach statistical significance (p > 0.05) partly because our MACC scheme was probably not sufficiently myelosuppressive to bring about a difference in the two groups. Granulocytopenia‐associated infections were infrequent in both groups: two episodes in 37 cycles of chemotherapy in the hypertransfusion group and three episodes in 43 cycles in the control group. Hypertransfusion was simple and safe, and the encouraging trend towards less marked myelosuppression in our hypertranfused group would warrant further studies using more intensive and myelosuppressive combination chemotherapy regimens.
Chemotherapy of advanced gastric cancer with 72‐hour continuous intravenous 5‐fluorouracil infusion at 2‐week intervals
Authors: Shah Amil , Macdonald Walter C. 
Published: February 2007

AbstractTwenty‐nine patients with advanced gastric adenocarcinoma were treated with 72‐hour continuous intravenous infusion of 5‐fluorouracil (30 mg/kg/24 hr) at 2‐week intervals. Six patients (21%) achieved partial response and four (14%) had stabilization of their disease. The median duration of partial response was 8 months, with a range of 5‐19 months. The median survival time for all patients from the start of chemotherapy was 8 months. Various prognostic factors important in determining response and survival are analyzed.
Chlorozotocin treatment of advanced gastrointestinal cancer
Authors: Veronesi A. , Magri M. D. , Tirelli U. , Galligioni E. , Figoli F. , Zagonel V. , Tumolo S. , Grigoletto E. 
Published: February 2007

AbstractFrom April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosuppression. Median survival was 3 months. At the dosage and schedule used, chlorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.
The samuel C. Harvey memorial lecture: Progress and responsibilities of educators in smoking control
Authors: Schuman Leonard M. 
Published: February 2007

AbstractIt is a privilege to have been asked to present the Harvey Lecture to this group of professional cancer educators. When I was asked by Dr. Kennedy to fill the void left by the illness of Henry Kaplan, he referred to his request in somewhat embarrassed terms, such as my obviously playing “>It is a privilege to have been asked to present the Harvey Lecture to this group of professional cancer educators. When I was asked by Dr. Kennedy to fill the void left by the illness of Henry Kaplan, he referred to his request in somewhat embarrassed terms, such as my obviously playing” I wish publicly to allay his embarrassment by reassuring him, your program committee, and all of you that I deem it an honor to substitute for a man who has contributed so much to radiobiology and hence to an understanding of the mechanisms of carcinogenesis and cancer therapy. Indeed, my only regret is that I am not now sitting among you listening to his remarks.
Combination chemotherapy with vincristine (NSC‐67574), procarbazine (NSC‐77213), prednisone (NSC‐10023) with or without nitrogen mustard (NSC‐762) (MOPP vs OPP) in children with recurrent brain tumors
Authors: Cangir Ayten , Ragab Abdelsalem H. , Steuber Philip , Land Vita J. , Berry Daisilee H. , Krischer Jeffrey P. 
Published: February 2007

AbstractSeventy‐three patients under 18 years of age with a recurrent central nervous system tumor were randomized to receive combination chemotherapy with MOPP or OPP. Patients were stratified according to the tumor type into four major disease‐categories: (1) medulloblastoma, (2) astrocytoma and other glioma, (3) ependymoma, and (4) miscellaneous tumors to provide equal distribution of patients for each treatment within each disease category. Evaluation of response was based on computerized brain scan findings. Thirty‐five patients received MOPP and 38 received OPP treatment. There were three complete and six partial remissions among patients receiving MOPP and one complete and five partial remissions among patients receiving OPP. In addition, six patients on MOPP had stable disease for seven to 21 months. Only two patients on OPP had stable disease(6 and 36 months). Most of responses in both treatment regimens occurred in patients with medullo‐blastoma and astrocytoma. Median duration of remission was ninemonths for the MOPP and 11 months for the OPP. Two patients on MOPP regimen had fatal myelosuppression. Although the more toxic MOPP regimen produced more responses than OPP in children, differences in the duration of response or survival were not statistically significant (P=.79 and P = .84, respectively).
Anthracycline‐induced cardiomyopathy in children: A report of six cases
Authors: Dearth J. , Osborn R. , Wilson E. , Kelly D. , Mantle J. , Rogers E. , Malluh A. , Crist W. 
Published: February 2007

AbstractAlthough anthracycline antibiotics are among the most useful chemotherapy agents, the risk of producing cardiomyopathy and the absence of a reliable noninvasive technique to predict subclinical cardiomyopathy remain a major problem. We retrospectively reviewed our experience with anthracyclines over a 5‐year period. Cardiomyopathy developed in 6 of 112 patients (5.3%) treated with anthracyclines and was fatal in 5 of the 6 patients. Our incidence and mortality rates are higher than those previously reported.
The diagnosis of pleural effusions—Are cancer markers clinically helpful?
Authors: Wardman A. G. , Bowen M. , Struthers L. P. L. , Cooke N. J. 
Published: February 2007

AbstractWe submitted 83 consecutive patients with pleural effusion to routine clinical investigation; 57 were diagnosed as malignant, 18 as benign, and 8 were not diagnosed. Pleural fluid and serum were analysed for carcinoembryonic antigen (CEA), acid glycoprotein (AGP), antichymotrypsin (ACT), C‐reactive protein (CRP), α2‐pregnancy associated glyco protein (α2‐PAG) and ferritin. Multivariate discriminant analysis was performed on the results of the protein measurements. CEA and ACT values in serum and fluid were found to give a good discriminating function between the benign and malignant groups. The use of such an analysis, in a clinical context, is discussed.
Cystathioninuria in patients with neuroblastoma
Authors: Rajnherc J. R. , van Gennip A. H. , Abeling N. G. G. M. , van der Zee J. M. , Voǔte P. A. 
Published: February 2007

AbstractUrinary excretion of cystathionine and dopa metabolites was analyzed in 61 patients with active neuroblastoma before, and at regular intervals during treatment. Thirty‐seven patients with clinical evidence of active neuroblastoma excreted elevated levels of cystathionine before treatment was initiated; six other patients showed cystathioninuria at some time during treatment with chemo‐ or radiotherapy. The cause of the cystathioninuria remains unidentified. No relationship between excessive cystathionine excretion and liver impairment or liver metastases was established; nor was there evidence to support a consistent correlation with the ratio of the sum of the excretion values for vanilglycolic acid and vanilglycol to the excretion of vanilacetic acid. Our results indicate that absence of cystathioninuria correlates with an early clinical staging and thus with a favorable prognosis. Isolated cystathioninuria does occasionally occur in patients with neuroblastoma, permitting a presumptive diagnosis until later evidence can be obtained. Determination of cystathionine excretion is essential for an extensive biochemical evaluation of patients with neuroblastoma.
Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors
Authors: Baumgartner Christoph , Bleher E. Arnold , del Re Guido Brun , Bucher Urs , Deubelbeiss Kurt A. , Greiner Richard , Hirt Andreas , Imbach Paul , Lüthy Annette , Odavic Ranko , Wagner Hans Peter 
Published: February 2007

AbstractNineteen patients with advanced malignant tumors, less than 20 years old were treated with intensive chemotherapy (vincristine 2 mg/m2 i.v. and adriamycin 60 mg/m2 i.v. on day −7; cyclophosphamide 45 mg/kg i.v. on days −6 to −3), total body irradiation (TBI, 600 rads on day −1) and autologous bone marrow transplantation (ABMT, day 0). Prior to this procedure induction of complete or partial remission by conventional therapy was attempted. Ten patients had intra‐abdominal non‐Hodgkin's lymphoma (NHL); three, yolk sac tumor; three, Ewing's sarcoma; and three, neuroblastoma. The supportive care included reverse isolation, immunoglobulin 400 mg/kg i.v. q 2 weeks, cotrimoxazole per os, and cell support as needed. No correlation between the bone marrow dose and the time of hematological reconstitution could be established. Five of seven patients with intraabdominal NHL stage III (transplanted in first remission) are surviving disease‐free for 5 +, 5 +, 20 +, 23 +, and 35 + months after ABMT. None of three patients with intra‐abdominal NHL stage IV is surviving (two of them were transplanted in second remission). One of three patients with yolk sac tumor is surviving disease‐free for 27+ months. There are no survivors among the patients with Ewing's sarcoma and neuroblastoma. Only one of 19 patients was lost due to therapeutic complications, while 12 died due to tumor. Regarding treatment results for advanced intra‐abdominal NHL, the procedure described here is comparable to the best conventional regimens. In vitro methods for tumor cell eradication in the collected bone marrow might further improve the results of ABMT.
Significance of mediastinal metastatic disease in Wilms' tumor of favorable histology
Authors: Cushing Barbara A. , Watts Frederick B. , Brough A. Joseph , Philippart Arvin I. , Das Lakshmi 
Published: February 2007

AbstractAlthough the results of the National Wilms' Tumor Study suggest poor outcome for children with metastases to intra‐abdominal, intracranial, skeletal, skin, diaphragm, or mediastinal sites, the incidence and course of mediastinal disease has not been described. Fifty‐four newly diagnosed Wilms' tumor patients at Children's Hospital of Michigan (1972‐1980) were studied for patterns of intrathoracic metastases. All had favorable histology; mean age (MA) at diagnosis was 4.5 years. Initial chemotherapy ranged from single agent to three‐drug combination (actinomycin, vincristine, adriamycin). Intrathoracic metastases occurred in 14 (26%) from 0‐28 months (median, 3.5 months) from diagnosis (MA, 5.8 years). Upon the discovery of intrathoracic metastases all received radiation (1,200‐2,000 rads) to the chest, some with supplementary doses to the mediastinum. Five children with parenchymal and one with parenchymal and hilar metastases appearing 0‐28 months after the time of diagnosis survive disease‐free 44‐127 months after metastases appeared (MA, 6.3 years). Eight children developed parenchymal and mediastinal metastases (MA, 5.4 years). Time from diagnosis to parenchymal metastases was 0‐7 months; time from diagnosis to mediastinal metastases was 0‐16 months; and in four, both sites appeared simultaneously. Death occurred in all eight patients 7‐25 months from diagnosis. Only one child had evidence of recurrence outside the chest. Potential risk factors and influence on survival are discussed.